Gilbert’s syndrome (also known as Meulengracht’s disease) was long regarded as a medical condition. In Central Europe, the syndrome affects around five to ten per cent of the population. Those affected are slimmer, have less body fat and better lipid metabolism profiles. They are protected against oxidative stress and have significantly lower inflammation levels – without having to lead a particularly healthy lifestyle.
“These thoroughly pleasant symptoms can be attributed to a slightly elevated bilirubin level, which results from a genetically determined underactivity of the enzyme UDP-glucuronosyltransferase,” explains Karl-Heinz Wagner, Department of Nutritional Sciences, University of Vienna: “People with Gilbert’s syndrome therefore have a natural defence against type 2 diabetes and cardiovascular disease.”
The research team has now also been able to demonstrate that a slightly elevated level of bilirubin in the blood also reduces the risk of colorectal cancer – particularly in women. And regardless of gender, bilirubin also reduces the risk of lung cancer.
This could be utilised therapeutically. Wagner: “If we succeed in artificially raising bilirubin levels and thereby influencing the associated metabolism, we could simulate the body’s own protective mechanism. This would also mean that we would need to take fewer medicines, such as those for lowering blood pressure and lipid levels, or drugs that regulate blood sugar levels.”
Targeted modification of bilirubin metabolism is complex, but research into this is already underway.
Bilirubin is a breakdown product of the red blood pigment (haemoglobin) which, when deposited in the skin, leads to jaundice.
References: University of Vienna
Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomisation analyses; BMC Med 2020:18(1):229; https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01703-w